Aptinyx Inc. (APTX) stock plummeted 56.84% in the pre-market trading session at the price of $1.01 after reporting results from its Phase-2b study evaluating NYX-2925.
NYX-2925 Phase-2b Study Results
On 7th April 2022, APTX reported clinical results from its Phase-2b study evaluating NYX-2925 in adult patients having severe Diabetic Peripheral Neuropathy. The patients dosed with NYX-2925 showed betterment in daily average pain score. However, NYX-2925 did not acquire a statistically substantial distinction from the placebo study on its primary endpoints. The drug had well-tolerated during the clinical study, with no safety issues or concerns reported.
The Phase-2b study was a double-blind, randomized, placebo-controlled clinical study devised to assess the safety and efficacy of NYX-2925. The study enrolled over 229 patients with high-level chronic DPN. The patients who qualified for the study received 50 mg doses of NYX-2925 once each day. The primary endpoint was the shift from baseline in average pain from 0 to 10 NRS during the twelfth week. Additional endpoints are pain while walking, pain during sleep, and everyday severe pain.
APTX is a clinical-stage biopharma firm that discovers, produces, and sells its proprietary tiny molecules to treat nervous system and brain diseases. The corporation currently has three clinically-developed product candidates for cognitive impairment and other nervous system indications. APTX is also promoting other molecules from its discovery forum to produce a diverse channel of NMDA modulators for neurologic conditions.
Current Market Updates
The management is quite disappointed after receiving the results of its NYX-2925 study. The clinical results demonstrate a complete failure in meeting the study’s primary endpoint. Unfortunately, the study data is not sufficient to pave the path forward in the progress of painful DP.
Nonetheless, Aptinyx looks ahead to publishing data from its Phase-2b fibromyalgia study by the mid Q3 of 2022. The management seems confident to advance its pipeline and manage the current balance sheet to allow readouts across its Phase-II studies in cognitive impairment, fibromyalgia, and PTSD.